📢 Watch out ! The first classic Watch edition of the year is out. The Exosomes and Other Extracellular Vesicles Immunowatch features several scientific articles from network and key insights of the field and its drug candidate pipeline by MabDesign’s business service unit. We would like to thank our two editors of chief, Florence Gazeau from Université Paris Cité and Jeanne Volatron from EVerZom for their guidance and support as well as our contributors Bio-Techne, Promega France and the EV study consortium. A special our two sponsors MYRIADE and Bio-Techne 👉 Download all the editions HERE: https://lnkd.in/e-bnHqMG #exosome #extracellularvesicle
EVerZom
Biotechnologie
Paris, Ile-de-France 4 499 abonnés
Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration
À propos
EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.
- Site web
-
https://everzom.com
Lien externe pour EVerZom
- Secteur
- Biotechnologie
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Ile-de-France
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2019
- Domaines
- extracellular vesicles, exosomes, bioproduction, drug delivery, regenerative medecine, biodrugs et cell culture
Lieux
-
Principal
Obtenir l’itinéraire
45, Rue des Saints-Pères
Paris, Ile-de-France, FR
Employés chez EVerZom
Nouvelles
-
🚀We are very to announce the signature of this new licence agreement with Erganeo at the basis of our first drug candidate EVerGel™. 🧬Thanks to this revolutionnary treatment, we are commited to bring therapeutic solution to patients with incurable diseases with high unmet medical needs like complex ano-perianal fistulas induced by Crohn's disease, stenosis, the healing of surgical anastomoses and Hidradenitis suppurativa. EVerGel ™ combines exosomes derived from stem cells with a heat-sensitive gel, enabling targeted and precise delivery. Thank you to Gabriel Rahmi Dr, Amanda Silva Brun and the whole EVerZom team for their efforts and dedication for this development. https://lnkd.in/eFiN_-Fe
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract. | BioSpace
biospace.com
-
We are more than happy to unveil our new therapeutic pipeline based on our exosome innovation platform. We are convinced that exosomes will be the key to treat high unmet medical needs pathologies in the future. We are now ready to move to clinic and plan a first in man in 24 months. Our first focus is digestive tissue healing, liver and kidney regeneration !! Thanks again to our great team and our key partners to make it possible! cc Julien Branchu-Capdevielle, PhD, Camille Simon, Thibaut Fourniols, Clément Bonamy, Elise Madec, Stanislas Loiseau, Christophe Wong, Bastien Thauvin, Isaure Rous, Pauline Talbot, Shony LEMIEUX, Maxence Duchemin, PhD, Maider Narzabal
-
Very happy to be at the Exosome based therapeutic Development Summit in Boston to discuss the clinical future of the exosome field with other industry leaders and to present our breakthrough technology to manufacture exosomes at large scale. cc Katie Gilligan OmniSpirant Limited Lior Shaltiel, PhD NurExone Biologic EXO Biologics Hugues Wallemacq EV Biologics Gianluca Roma TheraXyte BioScience Laura Sailor https://lnkd.in/eMxzaRQS
5th Exosome Based Therapeutic Development Summit
exosomebased-therapeutics.com